SCHEMBL11944199

SCHEMBL11944199

CS(=O)(=O)N1CCN(c2cnn(C3CCCC3)c(=O)c2OC2CCCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.44
▸ DCTPP1 Q9H773 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ LMNA P02545 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ CCNE1 P24864 4/20 0.36
▸ CDK2 P24941 4/20 0.36
▸ CCNE2 O96020 2/20 0.36
▸ SLC2A1 P11166 1/20 0.35
▸ SLC2A2 P11168 1/20 0.35
▸ SLC2A3 P11169 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ CDK4 P11802 2/20 0.35
▸ CCND1 P24385 2/20 0.35
▸ CDK6 Q00534 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CCNT1 O60563 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944264 0.99 ALDH1A1 (0.43) ALDH1A1DCTPP1SMN1; SMN2LMNANPSR1
SCHEMBL11944212 0.98 ALDH1A1 (0.43) ALDH1A1DCTPP1SMN1; SMN2LMNANPSR1
SCHEMBL11944222 0.90 ALDH1A1 (0.40) ALDH1A1DCTPP1SMN1; SMN2LMNANPSR1
SCHEMBL11944203 0.89 CCND1 (0.35) ALDH1A1DCTPP1CCNE1CDK2SLC2A1
SCHEMBL11944271 0.88 CCND1 (0.35) ALDH1A1DCTPP1CCNE1CDK2SLC2A1
SCHEMBL11944340 0.87 HRH3 (0.35) ALDH1A1DCTPP1CCNE1CDK2SLC2A1
SCHEMBL11944323 0.87 KDM4E (0.42) ALDH1A1CCNE1CDK2CCNE2KMT2A
SCHEMBL11944157 0.87 KDM4E (0.42) ALDH1A1CCNE1CDK2CCNE2KMT2A
SCHEMBL11944319 0.86 KDM4E (0.41) ALDH1A1CCNE1CDK2CCNE2KMT2A
SCHEMBL11944267 0.85 ALDH1A1 (0.40) ALDH1A1DCTPP1SMN1; SMN2LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885DCTPP1 625/4885SMN1; SMN2 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback